Loading clinical trials...
Loading clinical trials...
A Randomized, Single Blind, Placebo-controlled, Single Ascending Dose/Repeat Dose Cohort Study to Assess Safety, Tolerability, Pharmacokinetics and Immunogenicity of GSK1223249 in Patients With Relapsing Forms of Multiple Sclerosis.
Conditions
Interventions
GSK1223249
Saline placebo
Locations
2
Italy
GSK Investigational Site
Verona, Veneto, Italy
GSK Investigational Site
Lørenskog, Norway
Start Date
September 8, 2011
Primary Completion Date
January 23, 2012
Completion Date
January 23, 2012
Last Updated
November 24, 2020
NCT05359653
NCT06390930
NCT03401879
NCT06389968
NCT05834855
NCT06413602
Lead Sponsor
GlaxoSmithKline
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions